3,012 Shares in Medtronic plc (NYSE:MDT) Purchased by Fiducient Advisors LLC

Fiducient Advisors LLC purchased a new stake in Medtronic plc (NYSE:MDT) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,012 shares of the medical technology company’s stock, valued at approximately $273,000.

Other large investors have also made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in Medtronic in the third quarter valued at $27,000. Highline Wealth Partners LLC acquired a new stake in shares of Medtronic in the 3rd quarter valued at $27,000. Lynx Investment Advisory acquired a new position in shares of Medtronic during the second quarter valued at $28,000. Gleason Group Inc. bought a new position in shares of Medtronic in the 2nd quarter valued at about $42,000. Finally, Opal Wealth Advisors LLC acquired a new position in Medtronic in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MDT shares. Wells Fargo & Company upped their price target on Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research report on Friday, October 25th. Oppenheimer raised their target price on shares of Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a report on Wednesday, August 21st. Stifel Nicolaus increased their price objective on shares of Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a research report on Wednesday, August 21st. Finally, Barclays increased their target price on Medtronic from $104.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $95.36.

Medtronic Stock Up 0.3 %

Shares of NYSE:MDT opened at $90.55 on Thursday. The business’s 50-day moving average is $89.58 and its 200-day moving average is $84.03. Medtronic plc has a 1 year low of $69.32 and a 1 year high of $92.68. The company has a market capitalization of $116.11 billion, a price-to-earnings ratio of 32.93, a P/E/G ratio of 2.60 and a beta of 0.84. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.13 and a quick ratio of 1.61.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The company had revenue of $7.97 billion during the quarter, compared to the consensus estimate of $7.90 billion. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the business posted $1.20 EPS. Equities research analysts predict that Medtronic plc will post 5.44 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 11th. Investors of record on Friday, September 27th were paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend was Friday, September 27th. Medtronic’s dividend payout ratio is currently 101.82%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.